Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Kardigan, Inc. Common Stock

KARD

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

Last trade $13.20
Day change +$0.35 (+2.72%)
Day range $12.49 – $13.39
Volume 155,182
Market cap $1.20B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for KARD.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for KARD, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026
Revenue$0
Cost of revenue$0
Gross profit$0
Selling, general and administrative$18.87M
Research and development$56.37M
Total operating expenses$119M
Operating income-$119M
Interest expense$0
Income before taxes-$116.24M
Income taxes$0
Net income-$116.24M
Net income attributable to common shareholders-$116.24M
EBITDA-$119M
Basic earnings per share-$4.61
Diluted earnings per share-$4.61

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Over 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.